Pharmaceuticals company Marksans Pharma announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: The company reported a revenue of Rs 8,561.14 million in Q4FY26, representing a growth of 20.84% YoY compared to Rs 7,084.57 million in Q4FY25 and a growth of 13.48% QoQ against Rs 7,544.27 million in Q3FY26. Total Income: For Q4FY26, total income stood at Rs 8,912.88 million, an increase of 23.14% YoY from Rs 7,237.95 million and 15.07% QoQ from Rs 7,745.71 million. Profit After Tax (Net Profit): Net profit for Q4FY26 was Rs 1,490.32 million, witnessing a growth of 64.27% YoY from Rs 907.26 million and a 31.09% increase QoQ from Rs 1,136.90 million. Annual Revenue from Operations: For FY26, consolidated revenue reached Rs 29,509.38 million, up 12.51% from Rs 26,228.45 million in FY25. Annual Profit After Tax: The consolidated net profit for FY26 stood at Rs 4,200.64 million, marking a growth of 9.79% over Rs 3,826.19 million in FY25. Earnings Per Share (EPS): The basic EPS for FY26 increased to Rs 9.22, compared to Rs 8.40 in the previous year. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 3,615.73 million, reflecting a YoY growth of 20.78% compared to Rs 2,993.57 million and a QoQ growth of 6.43% from Rs 3,397.29 million. Total Income: Standalone total income stood at Rs 3,890.48 million for the quarter, up 27.14% YoY and 9.41% QoQ. Profit After Tax (Net Profit): The company recorded a standalone net profit of Rs 919.23 million in Q4FY26, representing a significant increase of 144.53% YoY from Rs 375.91 million and 50.91% QoQ from Rs 609.12 million. Annual Revenue from Operations: Standalone annual revenue for FY26 was Rs 13,414.76 million, compared to Rs 11,743.74 million in FY25. Annual Profit After Tax: Annual standalone net profit grew to Rs 3,006.98 million in FY26 from Rs 1,882.72 million in FY25. Business Highlights: Segment Performance: The group operates exclusively in a single reportable segment, namely "Pharmaceuticals," as per Ind AS 108. Dividend: The Board of Directors has recommended a final dividend of Rs 0.90 per Equity Share of face value Re 1/- (90%) for the financial year 2025-26. Subsidiary Expansion: During Q4FY26, the company incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland (effective January 16, 2026) and Marksans (Canada) Inc. in Canada (effective January 22, 2026). Labour Code Impact: Following the implementation of new Labour Codes and a subsequent revision of the salary structure, the company recognized a net impact of Rs 26.09 million as Employee Benefits Expense for the financial year ended March 31, 2026. Foreign Exchange Performance: Net exchange gains for the full year FY26 amounted to Rs 500.95 million on a consolidated basis and Rs 474.26 million on a standalone basis. Result PDF